Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Next Previous
Trial Profile

ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumasiran (Primary)
  • Indications Primary hyperoxaluria type 1
  • Focus Registrational; Therapeutic Use
  • Acronyms ILLUMINATE-A
  • Sponsors Alnylam Pharmaceuticals

Most Recent Events

  • 13 Feb 2024 Status changed from active, no longer recruiting to completed.
  • 01 May 2023 36-month results presented at the 118th Annual Meeting of the American Urological Association.
  • 06 Oct 2022 According to an Alnylam Pharmaceuticals media release, the USFDA has approved a label expansion for OXLUMO (lumasiran), indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate (UOx) and plasma oxalate (POx) levels in pediatric and adult patients. The approval is based on results of this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top